X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

NUVL

Closed

Nuvalent Inc

78.05
+1.75 (+2.29%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 76.3
Day's Range: 76.265 - 79.3714
Send
When Written:
 
23.85
Nuvalent Inc is a clinical-stage biopharmaceutical company that focuses on developing precision medicines for patients with cancer. The company was founded in 2019 and is headquartered in Cambridge, Massachusetts. Nuvalent's technology platform enables the discovery and development of small molecule drugs that target specific genetic mutations associated with cancer. The company's lead product candidate, NUV-422, is a potent and selective inhibitor of the kinase FGFR2, which is being developed for the treatment of patients with advanced solid tumors that harbor FGFR2 alterations. Nuvalent is also developing a pipeline of additional precision oncology therapies for patients with other genetic mutations. The company has raised over $220 million in funding to date from investors such as MPM Capital, Deerfield Management, and Fidelity Management & Research Company.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X